Treating the S1 protein with neuraminidase appeared to completely abolish antibody responses, suggesting that cross‐reactivity was due to antibodies binding with the terminal sialic acids of complex glycans in SCV2 Spike S1.[19] In contrast, we found SCV2‐reactive antibodies for both SCV2 whole Spike and RBD constructs in Cambodian participants with and without acute or prior malaria exposure. This evidence concerns the gene PSMD1 and malaria.